COMMUNIQUÉS West-GlobeNewswire

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

19/12/2024 - 13:00

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., [...]

Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights

19/12/2024 - 13:00

– Completed US$7.7 million financing and reverse takeover to take Company public – Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company [...]

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

19/12/2024 - 13:00

Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology [...]

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

19/12/2024 - 13:00

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4 [...]

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

19/12/2024 - 13:00

Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s Macroglobulinemia SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: [...]

NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics

19/12/2024 - 13:00

Aarhus, Denmark, 19 December 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announced that findings [...]

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

19/12/2024 - 13:00

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected [...]

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

19/12/2024 - 13:00

Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and Knowledge in Fill and [...]

NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate

19/12/2024 - 13:00

KdT has formed a new company to develop NGM313 in a rare disease indication NGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered [...]

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

19/12/2024 - 07:00

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints Prasinezumab continues to be well tolerated and no new safety signals were observed Roche is [...]

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024

19/12/2024 - 07:00

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Company and Zelluna [...]

NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics

19/12/2024 - 07:00

Aarhus, Denmark, 19 December 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announced that findings [...]

Crossject confirme la disponibilité opérationnelle de sa chaîne de fabrication de ZEPIZURE® avec un nouvel audit ISO réussi sur son système de gestion de la qualité

19/12/2024 - 07:30

Crossject passe à nouveau avec succès l'audit ISO 13485 pour ses sites de Dijon et Gray La société monte en puissance sa chaîne de production pour préparer la commercialisation aux États-Unis. Dijon, 19 décembre 2024, [...]

Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management System

19/12/2024 - 07:30

Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France) Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024, 07:30 CET -- [...]

Valneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of India

19/12/2024 - 08:00

Saint-Herblain (France), Pune, (Inde), le 19 décembre 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, et le Serum Institute of India (SII), plus grand fabricant de vaccins [...]

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

19/12/2024 - 08:00

Saint-Herblain (France), Pune, (India), December 19, 2024 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest manufacturer of vaccines by [...]

AGM Statement

19/12/2024 - 08:00

DXS INTERNATIONAL PLC (AQSE: DXSP) DXS AGM 2024 Statement The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems [...]

EssilorLuxottica: Le Groupe Prada et EssilorLuxottica annoncent le renouvellement pour 10 ans de leur accord de licence

19/12/2024 - 08:00

Le Groupe Prada et EssilorLuxottica annoncent le renouvellement pour 10 ans de leur accord de licence Ce renouvellement traduit la forte confiance, le respect et la qualité de la collaboration entre les deux entreprises [...]

EssilorLuxottica: Prada Group and EssilorLuxottica announce ten-years licensing renewal

19/12/2024 - 08:00

Prada Group and EssilorLuxottica announce ten-years licensing renewal The renewal is a testament to the strong confidence, trust and collaboration between the two companies Milan, Italy and Paris, France (19 December [...]